CorMedix Inc. to Report Third Quarter 2018 Financial Results on Wednesday, November 14

BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 6, 2018 / CorMedix Inc. (NYSE: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2018, after the market close on Wednesday, November 14, 2018 and will host a corporate update conference call the same day at 4:30pm Eastern Time.

Wednesday, November 14 at 4:30pm Eastern Time
Domestic: 877-407-9124
International: 201-689-8584
Conference ID: 13684636
Webcast: http://www.investorcalendar.com/event/40032

Replays, Available through November 28 2018:
Domestic: 877-481-4010
International: 919-882-2331 40032
Replay PIN: 40032

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Neutrolin®, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters, currently in Phase 3 development for patients undergoing chronic hemodialysis. Such infections cost the U.S. healthcare system approximately $6 billion annually and contribute significantly to increased morbidity and mortality. Neutrolin has FDA Fast Track status and is designated as a Qualified Infectious Disease Product, which provides the potential for priority review of a marketing application by FDA and allows for 5 additional years of QIDP market exclusivity in the event of U.S. approval. Neutrolin is already marketed as a CE Marked product in Europe and other territories. In parallel, CorMedix is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with active programs in surgical sutures and meshes, and topical hydrogels. The company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. For more information, visit: www.cormedix.com.

Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors
617-535-7746

SOURCE: CorMedix, Inc.



View source version on accesswire.com:
https://www.accesswire.com/526265/CorMedix-Inc-to-Report-Third-Quarter-2018-Financial-Results-on-Wednesday-November-14

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.